Simcere Pharmaceutical Group Limited announced that, on November 28, 2023, a new indication of the Sanbexin®? sublingual tablets (Edaravone and Dexborneol sublingual tablets), which was jointly developed by the Group and Neurodawn Pharmaceutical Co. Ltd. ("NDA") has obtained the Clinical Trial Approval issued by the National Medical Products Administration (Guo Jia Yao Pin Jian Du Guan Li Ju) (the "NMPA") of China, which is intended to be used in the clinical trials of Sanbexin®?

Sublingual tablets for the prophylactic treatment of Post Stroke Cognitive Impairment (PSCI) in patients with Acute Ischemic Stroke ("AIS").